New Treatments in Chronic Liver Disease

31st ANNUAL

FRIDAY, MARCH 18 – SUNDAY, MARCH 20, 2016

Pre-Conference: Friday, March 18, 2016
Main Conference: Saturday, March 19 – 20, 2016

Estancia La Jolla • La Jolla, California
Course Introduction

**COURSE OVERVIEW**

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies in 2015, and the cumulative clinical experience with these compounds. The second will be on future therapies that will shorten duration and lower cost of a cure. As well, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters.

We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2016, we see new combinations of DAAs in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and NS5A inhibitors. Some of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease has been included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. There will be updates provided for the treatment of AIH, PBC and PSC with a focus on the newly-approved regimen for PBC. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of complications in the transplant candidate.

**ACCREDITATION**

Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (AC-CME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of **13.5 AMA PRA Category 1 Credit(s)™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

**Credit Breakdown:**
- Pre-Conference (Fri): 3.5
- Main Conference (Sat-Sun): 10

**Nurse Practitioners:** This education activity will be submitted to the American Association of Nurse Practitioners for approval of up to 13.5 contact hours of accredited education.

**Physicians Assistants:** Conference organizers plan to request 13.5 hours of AAPA Category 1 CME credit from the Physician Assistant Review Panel. Total number of approved credits yet to be determined.

**EDUCATIONAL GRANTS**

This course is supported, in part, by educational grants from industry, in accordance with ACCME accreditation Standards for Commercial Support. At the time of printing, a complete listing of commercial supporters was not available. Appropriate acknowledgement will be given to all supporters at the time of the educational activity.

**EDUCATIONAL OBJECTIVES**

After participating in this course, attendees should be able to:

- Understand the details of the AASLD guidelines for treatment of HCV using DAAs in IFN-free regimens.
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss therapies for HCV including NS5A, protease and polymerase inhibitors.
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Discuss future treatment paradigms for HCV direct-acting antiviral drug.
- Describe the diagnosis and treatment of AIH, PBC and PSC.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Review the risks for NAFLD and NASH and the relationship of these conditions to the American diet and lifestyle.
PRE-CONFERENCE OVERVIEW

We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients with all-oral antiviral therapies including all currently approved regimens in the US. We will include patients in special populations such as HIV-coinfected, ESLD, post- liver transplant and end-stage renal disease.

PRE-CONFERENCE

Friday, March 18, 2016

12:30 p.m. Registration
1 p.m. Welcome & Introduction
Paul Pockros, MD
1:10 p.m. Update on HCV Diagnostics
Paul Pockros, MD
1:40 p.m. Update on Current therapy with All-Oral Regimens
Paul Pockros, MD

MAIN CONFERENCE

Saturday, March 19, 2016

7:30 a.m. Registration, Breakfast & View Exhibits
8 a.m. Welcome & Introduction
Paul Pockros, MD
8:15 a.m. VIRAL HEPATITIS
Moderator: Catherine Frenette, MD
8:30 a.m. HCV – Current Therapies 2016
Kris Kowdley, MD
9 a.m. HCV Therapies in Development
Paul Pockros, MD
9:45 a.m. Break & View Exhibits
10:15 a.m. HBV Therapies in Development
Tram Tran, MD
11 a.m. Debate
Do We Need Any More Therapies for HCV? - No
Kris Kowdley, MD
11:05 a.m. Debate
Do We Need Any More Therapies for HCV? - Yes
Paul Pockros, MD
11:10 a.m. Panel Discussion
Kris Kowdley, MD
Paul Pockros, MD and Tram Tran, MD
11:45 a.m. Lunch
PBC, PSC, AIH and NASH
Moderator: Jill Lane, MD
1 p.m. PBC and PSC
John Vierling, MD
1:45 p.m. NASH
Kris Kowdley, MD
2:30 p.m. Break & View Exhibits
3 p.m. AIH
John Vierling, MD

Saturday (continued)

3:45 p.m. Debate
Expand the Use of OCA to Other Indications Now
Kris Kowdley, MD
3:50 p.m. Debate
Don’t Expand the Use of OCA to Other Indications Now
John Vierling, MD
4 p.m. Panel Discussion
Hashem El-Serag, MD, MPH, Kris Kowdley, MD and John Vierling, MD
4:30 p.m. Adjourn

Sunday, March 20, 2016

7:30 a.m. Breakfast & View Exhibits
8 a.m. William Haubrich Lecturer
HCC in 2016
Hashem El-Serag, MD, MPH
8:45 a.m. NAFLD, NASH and American Health Behavior
Norman Sussman, MD
9:30 a.m. Liver Transplantation in 2016
Catherine Frenette, MD
10:15 a.m. Break & View Exhibits
10:30 a.m. Debate
Traveling Outside Your Region Doesn’t Help you with a LT
Catherine Frenette, MD
10:35 a.m. Debate
Traveling Outside Your Region Does Help you with a LT
Norman Sussman, MD
11 a.m. Panel Discussion
Catherine Frenette, MD and Norman Sussman, MD
11:45 a.m. Adjournment
Faculty

**Course Director**

Paul Pockros, MD, FACG  
Director, Liver Disease Center  
Scripps Clinic  
Director of Clinical Research  
Scripps Translational Science Institute  
La Jolla, California

**Scripps Faculty**

Catherine Frenette, MD  
Medical Director of Liver Transplantation  
Director of Center of Excellence for HCC  
Scripps Center for Cell and Organ Transplantation  
Scripps Clinic  
La Jolla, California

Jill Lane, MD  
Division of Gastroenterology/Hepatology  
Scripps Clinic  
La Jolla, California

Bahar Madani, MD  
Scripps Center for Cell and Organ Transplantation  
Scripps Clinic  
La Jolla, California

Yuki Rosenkoetter, PA-C, MPAs  
Division of Gastroenterology/Hepatology  
Scripps Clinic  
La Jolla, California

**Guest Faculty**

Hashem B. El-Serag, MD, MPH  
Investigator, Clinical Epidemiology & Comparative Effectiveness Program  
Michael E. DeBakey VA Medical Center  
Professor and Chief  
Department of Medicine  
Baylor College of Medicine  
GI Section Chief  
Michael E. DeBakey VA Medical Center  
Houston, Texas

Kris Kowdley, MD, FACP, FACP, FACP, FACP  
Director of the Liver Care Network and Organ Care Research  
Swedish Medical Center  
Seattle, Washington

Norman Sussman, MD  
Associate Professor, Liver Center  
Baylor College of Medicine  
Houston, Texas

Tram T. Tran, MD, FACG  
Medical Director  
Liver Transplant and Hepatology  
Associate Professor of Medicine  
Cedars Sinai Medical Center  
Los Angeles, California

John Vierling, MD, FACP  
Professor of Surgery  
Chief of Hepatology  
Director of Baylor Liver Health  
Baylor College of Medicine  
Houston, Texas

**Faculty Disclosure**

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Employees of a commercial interest with business lines or products relating to the content of the CME activity will not participate in the planning or any accredited portion of the conference. Disclosure will be made to all participants at the conference location, prior to the educational activity commencement.

Conference Location

**Estancia La Jolla Hotel**  
9700 N. Torrey Pines Road, La Jolla, California 92037  
855-318-7602  
estancialajolla.com

Please make your own sleeping room reservation, no later than March 3, 2016. Mention you are with the Scripps Liver Disease conference to receive the reduced rate of $199 per night, plus the $12 hospitality service fee (discounted from $17), which includes:  
Welcome beverage at check-in, guest room bottled water daily, wireless internet access in guest room and common area, daily newspaper, in room coffee & morning coffee service in Trinitas Cellars Wine Bar, local & 800 call access and access to Fitness Center, Internet Office and Pool area.

Download the Scripps CME App

All conference information including a detailed agenda, faculty listing, faculty disclosures, industry support, attendee list, and course materials can be found on the free Scripps CME conference app for iPhone, iPad, Android, and BlackBerry. To download the app on your smart phone or other device visit the appropriate app store and search ScrippsCME (must be one word). The app is free of charge and will be continuously updated during and after the course.

To access the site using your cell phone or computer’s web browser: http://www.grupio.com/ScrippsCME
Conference Fees & Registration

PRE-CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website) and internet in meeting space.
Not Included: Printed course syllabus, meals, travel costs, parking and lodging.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 19</th>
<th>Feb 20 - Mar 11</th>
<th>On-site after Mar 11</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$100</td>
<td>$125</td>
<td>$150</td>
</tr>
</tbody>
</table>

MAIN CONFERENCE FEES
Included: Course tuition, access to conference materials (via mobile app and conference website), internet in meeting space, breakfasts, breaks and lunch.
Not Included: Printed course syllabus, travel costs, parking, lodging and dinners.
Please note: there are no day rates available for this conference.

<table>
<thead>
<tr>
<th></th>
<th>Thru Feb 19</th>
<th>Feb 20 - Mar 11</th>
<th>On-site after Mar 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$305</td>
<td>$330</td>
<td>$355</td>
</tr>
<tr>
<td>Non-Physician</td>
<td>$235</td>
<td>$260</td>
<td>$285</td>
</tr>
<tr>
<td>Fellows and Residents</td>
<td>$165</td>
<td>$190</td>
<td>$215</td>
</tr>
</tbody>
</table>

CONFERENCE COURSE MATERIALS
Access to Conference App (included in cost of pre and main conference fees) $100

By completing this registration form and returning it to Scripps you are acknowledging compliance with all attendance policies.

Please Print Clearly. Should we have any conference communications or updates please provide your direct contact information.

FIRST NAME, MI, LAST NAME

DEGREE (MD, DO, PhD, RN, ETC)

BADGE NAME IF DIFFERENT FROM ABOVE

AFFILIATION/HOSPITAL/COMPANY

SPECIALTY

DIRECT MAILING ADDRESS

CITY / STATE / ZIP CODE

DIRECT TELEPHONE

FAX

EMAIL

Please indicate any special needs (including dietary restrictions).

Special requests will be considered and accommodated in full compliance with the Americans with Disabilities Act (ADA).

Payment method ______ Check, please make checks payable to Scripps (in U.S. dollars only).

If paying by credit card, please fill out the information below. ______ Visa ______ MasterCard ______ Amex ______ Discover

CREDIT CARD NUMBER

EXPIRATION DATE

SECURITY CODE ON CARD (required)

NAME ON CARD

SIGNATURE

BILLING ADDRESS IF DIFFERENT FROM ABOVE
Conference presentations will be available via mobile app and conference website. Internet will be available in the meeting space.

Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAA’s.

Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.

Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.

TARGET AUDIENCE

Hepatologists
Gastroenterologists
Infectious Disease Specialists
Nurse Practitioners

Physician Assistants
Nurses
Residents/Fellows
and others desiring an update in these specialty areas